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Abstract
Tumor necrosis factor- converting enzyme (TACE) is a membrane-anchored, Zn-dependent metalloprotease, which belongs to the
ADAM (a disintegrin and metalloprotease) family. TACE functions as a membrane sheddase to release the ectodomain portions of many
transmembrane proteins, including the precursors of TNF, TGF, several other cytokines, as well as the receptors for TNF, and
neuregulin (ErbB4). Mice with TACEZn/Zn null mutation die at birth with phenotypic changes, including failure of eyelid fusion, hair and
skin defects, and abnormalities of lung development. Abnormal fetal heart development was not previously described. Herein, we report that
TACEZn/Zn null mutant mice by late gestation exhibit markedly enlarged fetal hearts with increased myocardial trabeculation and reduced
cell compaction, mimicking the pathological changes of noncompaction of ventricular myocardium. In addition, larger cardiomyocyte cell
size and increased cell proliferation were observed in ventricles of TACEZn/Zn knockout mouse hearts. At the molecular level, reduced
expression of epidermal growth factor receptor, attenuated protein cleavage of ErbB4, and changes in MAPK activation were also detected
in TACEZn/Zn knockout heart tissues. The data suggest that TACE-mediated cell surface protein ectodomain shedding plays an essential
and a novel regulatory role during cardiac development and modeling.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
A wide variety of cell surface transmembrane proteins,
including cytokines, growth factors, receptors, and adhesion
molecules, can be released from the cell surface by a pro-
teolytic process, which is referred to as “ectodomain shed-
ding” (Kheradmand and Werb, 2002). Since many cyto-
kines and growth factors are initially synthesized as
transmembrane precursors with low biological activity or
limited accessibility, specific cleavage of these precursor
proteins to release their active soluble forms is one of the
key regulatory steps to change their biological activities. On
the other hand, cleavage of the extracellular portions of the
transmembrane receptors can downregulate these receptor
functions by abrogating the ligand binding activity. There-
fore, protein ectodomain shedding may regulate cell prolif-
eration, differentiation, and survival through changing the
interaction of cells with their surrounding environment in
multiple ways. Tumor necrosis factor- converting enzyme
(TACE, or ADAM17) is one of the well-characterized cell
membrane sheddases (Black, 2002), and belongs to the
family of a disintegrin and metalloprotease (ADAM) (Pri-
makoff and Myles, 2000). TACE has Zn-dependent metal-
loprotease activity that cleaves the transmembrane form of
tumor necrosis factor- (TNF-) and releases an active and
soluble form of TNF- (Moss et al., 1997; Black et al.,
1997). However, specific protein ectodomain shedding by
TACE is not restricted to TNF-. Many cell membrane-
bound proteins, including TGF-, L-selectin, amyloid-
precursor protein, Notch-1 receptor, TRANCE, ErbB4,
TNF receptors (p75 and p55), as well as Type II IL-1
receptor, have been reported to be cleaved by TACE in
certain cell types under certain conditions (Sunnarborg et
al., 2002; Peschon et al., 1998; Lum et al., 1999; Brou et al.,
2000; Rio et al., 2000; Buxbaum et al., 1998).
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Abrogation of TACE’s function in mice by genetically
deleting zinc-binding domain (TACEZn/Zn) resulted in
perinatal lethality with several observable phenotypes, in-
cluding failure of eyelid fusion, hair and skin defects, and
abnormal lung development (Peschon et al., 1998; Zhao et
al., 2001). This set of characteristics does not occur in
TNF--deficient mice (Marino et al., 1997; Pasparakis et
al., 1996). However, some phenotypes do closely resemble
the phenotypic features of TGF- knockout mice (Luetteke
et al., 1993). Subsequent studies showed that cells from
TACEZn/Zn mice release little TGF- (Sunnarborg et al.,
2002; Peschon et al., 1998). However, TGF- null mutant
mice do not die prematurely, suggesting that TACE has
additional substrates required for development of some im-
portant organs that are essential for survival. One of such
organ may be the heart. The abnormal myocardial develop-
ment phenotype reported herein has not been described in
the previous studies.
The heart is the first organ to form during embryonic
development in vertebrates. It arises through a complex
series of morphogenetic interactions involving cells from
several embryonic origins (Olson and Srivastava, 1996;
MacLellan and Schneider, 2000). The early heart develop-
mental process includes formation of the primitive cardiac
tube, looping of the cardiac tube to the right, and chamber
specification and formation. Then, during maturation of the
fetal heart, cardiomyocytes exhibit two related but distinct
modes of growth that are highly regulated. The ventricular
mass of the fetal heart is augmented by cardiomyocyte
proliferation, also termed hyperplasia, which decreases pro-
gressively in late gestation and ceases soon after birth.
Increases in cardiac mass postnatally are achieved prepon-
derantly through increased cell volume, termed hypertro-
phy, and not by cell proliferation, since the cardiomyocytes
have permanently exited the cell cycle. These complicated
cardiac morphogenetic events must be coordinated by many
fine-tuned, as yet unidentified factors. Changes in these
homeostatic factors, such as TACE, may contribute to de-
velopmental anomalies of the heart.
Mutation of a wide variety of genes in mice results in
abnormal development of the myocardial wall. For exam-
ple, mice homozygous for a null mutation in the gene
encoding retinoid X receptor- display ventricular chamber
hypoplasia and muscular ventricular septal defects (Sucov
et al., 1994). A similar phenotype is also seen in mice
carrying mutation in N-myc, TEF1, NF1, and -ARK1
genes (Brannan et al., 1994; Chen et al., 1994; Charron et
al., 1992; Jaber et al., 1996). In contrast, null mutations in
several other genes, such as heparin-binding epidermal
growth factor (HB-EGF), ErbB2, HOP, PTEN, and phos-
pholamban, result in myocardial hyperplasia, and/or hyper-
trophy as well as reduced contractile function (Iwamoto et
al., 2003; Ozcelik et al., 2002; Crone et al., 2002; Shin et al.,
2002; Crackower et al., 2002; Schmitt et al., 2003). Null
mutation of FKBP12 results in a defect in the compact layer
of ventricular myocardium with an increased trabecular
layer, resembling the human disorder, “noncompaction of
the ventricular myocardium” (Shou et al., 1998; Chin et al.,
1990). The diversity of genes affecting myocardial growth
suggests that cardiac development is particularly sensitive
to perturbations. Although many cardiac malformations are
well characterized anatomically and physiologically, there
is still little understanding of the genetic basis of these
abnormalities. Herein, we show that null mutation of the
TACE gene induces abnormal myocardial development in
TACEZn/Zn knockout mice, and altered cellular signal
transduction. This is the first time that a congenital fetal
myocardial growth phenotype due to abrogation of endog-
enous TACE activity has been characterized.
Materials and methods
Mice
TACEZn/Zn mutant mice (C57BL/6) with inactivated
TACE activity were kindly provided by Dr. Jacques Pe-
schon at Amgen (Seattle, WA) (Peschon et al., 1998). Ho-
mozygous TACEZn/Zn null mutant (/) mice were pro-
duced by cross-breeding TACE heterozygous (/) mice
overnight. The presence of a vaginal plug was counted as
gestation day 0.5 (E0.5). Fetal hearts were isolated under a
dissecting microscope from E15.5 to newborn (P1) mice,
and TACE genotypes were verified by genomic DNA PCR
analysis as documented previously (Zhao et al., 2001).
Heart histology
Fetal mice at different gestational ages were fixed in 4%
paraformaldehyde and embedded in paraffin. Transverse sec-
tions across the middle part of the heart were obtained at 6 m
thickness and mounted onto HistoGrip-coated microscopic
slides (Zymed, San Francisco, CA). Hematoxylin and eosin
(H&E) staining was used to analyze the heart morphological
differences between wild-type and TACEZn/Zn null mutant
mice.
Total RNA isolation and quantitative RT-PCR
The total RNA was isolated from heart tissues by using
a Qiagen RNeasy kit (Qiagen Inc., Santa Clarita, CA). Total
RNA (2 g) was added to a 20-l reverse transcription
reaction mixture with 200U SUPERSCRIPT II (Invitrogen,
Carlsbad, CA) and incubated at 42°C for 60 min. The RT
reaction product was further diluted and applied to PCR
analysis. The competitive RT-PCR method for quantifica-
tion of TACE gene expression has been described previ-
ously (Shi et al., 1999).
Real-time quantitative RT-PCR analysis was performed
on iCycler-iQ system (Bio-Rad Laboratories, Hercules, CA)
by using SYBR Green I dye detection. The reactions were
assembled following manufacturer’s recommendation.
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Briefly, 25 l of reaction mixture contains 1  iQ SYBR
Green Supermix (Bio-Rad), 200 nM forward and reverse
primers, and the cDNA template from the RT reaction
sample. The PCR conditions are 3 min at 95°C followed by
40 cycles of 10 s at 95°C, 30 s at annealing temperature, and
30 s at 72°C. The specificity of PCR was verified by mea-
suring the melting curve of the PCR product in the end of
reaction. Fluorescent data are specified for collection during
the 72°C step. The relative cDNA ratio was calculated by
using CP [CP, Crossing point that is equivalent to
threshold cycles (Ct); Pfaffl, 2001]. The PCR primer se-
quences are: ANF (GGTCTTGCCTCTCCACTCT and CA-
GAAGCCAAAGAAGCACATCA); BNP (GAGTCCT-
TCGGTCTCAAGGCAG and GCCCAAACGACTGACG-
GATC); MyHC- (GACATTGGTGCCAAGAAG and
CGAACGTTTATGTTTATTGTG); MyHC- (CAAG-
GGCCTGAATGAGGAG and CCACCTAAAGGGCTGT-
TGC); skeletal -actin (AATGCTTCTAGGCGCACTCG
and GTACACGTCAAAAACAGGCGC); cardiac -actin
(CTCTCTGTCCACCTTCCAG and TACAATGACTGAT-
GAGAGATGG). GAPDH was used as reference control to
normalize equal loading of template cDNA.
Immunohistochemistry
Tissue sections were deparaffinized, rehydrated, and pro-
cessed for immunohistochemical studies by using Zymed
Histostain-Plus system (Zymed). TACE antibody was pur-
chased from Santa Cruz Biotech (Santa Cruz, CA). Nonim-
mune serum was used as negative control, and lung section
staining was used as a positive control as reported previ-
ously (Zhao et al., 2001).
BrdU labeling and cell proliferation in vivo
BrdU labeling during DNA synthesis in mitotic cells was
used to measure cell proliferation rate. Briefly, BrdU (0.1
mg/g body weight) was intraperitoneally injected into the
pups 3 h before heart isolation. The paraformaldehyde-fixed
and paraffin-embedded heart tissue sections were then im-
munostained by using a BrdU immunostaining kit (Zymed)
to detect proliferating cells with nuclear incorporated BrdU.
DAB was used as the chromogenic substrate in final color
development. The percentages of positively stained cells
were counted in five randomly selected fields by micros-
copy at high magnification.
Cell apoptosis
The apoptotic cells in heart tissue sections were detected
by using ApopTag kit (Intergen, Purchase, NY). Briefly, the
deparaffinized tissue sections were treated with 20 g/ml
proteinase K for 15 min. The endogenous peroxidase was
then quenched in 3% H2O2 in PBS for 5 min. The free
3-OH ends of DNA fragments in apoptotic cells were
labeled with digoxigenin (DIG)–dNTP by terminal deoxy-
nucleotidyl transferase for 1 h at 37°C. The labeled DIG
was then detected by immunostaining with anti-DIG anti-
body-conjugated HRP. DAB was used as a chromogenic
substrate, and the slides were counterstained with 0.5%
methyl green.
Western blot
Detection of a specific protein has been previously de-
scribed (Zhao et al., 2000). Briefly, heart tissues were ho-
mogenized on ice in RIPA buffer: 1% Nonidet P-40, 0.25%
sodium deoxycholate, 0.1% SDS, 50 mM sodium floride, 5
mM EDTA, and freshly added 1 mM PMSF, 0.2 U/ml,
aprotinin, and 1 mM sodium orthovanadate. Protein con-
centration was estimated by the Bradford method (Bio-
Rad). Total tissue lysate proteins (30 g) were loaded in
each lane for SDS-PAGE, and the separated proteins were
transferred to Immobilon-P membrane (Millipore, Bedford,
MA). The membrane was then blocked for nonspecific bind-
ing overnight at 4°C by incubating membrane in either 5%
fat-free drymilk in TBST (10 mM Tris–HCl, pH 7.4, 150
mM NaCl, and 0.1% Tween 20) for specific protein detec-
tion, or 3% bovine serum albumin in TBST for protein
phosphorylation detection. Primary antibody was diluted in
blocking buffer and incubated with the membrane for 1 h at
room temperature. After washing the membrane in TBST
(10 min  4), HRP-conjugated secondary antibody was
added for 45 min at room temperature. The antibody de-
tected protein bands were visualized by ECL reagent (Am-
ersham, Piscataway, NJ), and recorded on Kodak BioMax
film. Antibodies for EGFR, ErbB4, ERK, JNK, pJNK, and
p38 were purchased from Santa Cruz, and antibodies for
pERK and pp38 were from Cell Signaling Technology
(Beverly, MA).
Results
TACE expression in mouse fetal heart
In order to evaluate the role of TACE during fetal heart
development, expression of TACE mRNA in mouse fetal
heart during different developmental stages was determined
by competitive RT-PCR (Fig. 1A and B). Expression of
TACE at mRNA level was the highest at early embryonic
stage (E11.5) and was reduced during mid–late gestation
(E14.5 to P1). Interestingly, there was a slight increase of
TACE mRNA expression at late embryonic stage (E18.5).
Cellular localization of TACE protein in fetal heart was
analyzed by immunohistochemistry (Fig. 1C and D). TACE
protein was detected in a dispersed pattern in both atrium
and ventricle at E16.5. However, the intensity of staining
was stronger on the endocardial side of the myocardial wall
compared with the compact layer of myocardium on the
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epicardial side, and particularly among the trabecular struc-
tures.
TACEZn/Zn null mutant mice exhibit enlarged heart by
late gestation stage
A significantly enlarged fetal heart size, including both
atria and ventricles, was observed in TACEZn/Zn knock-
out mice after E18.5 compared with wild-type mice. The
abnormal enlargement of heart size in TACEZn/Zn mice
reached a maximum on postnatal day 1 (Fig. 2A), when
most TACEZn/Zn knockout mice died. Histologically the
atrial and ventricular chambers and the thickness of ven-
tricular myocardium at E15.5 were similar between wild-
type and TACEZn/Zn knockout mice (Fig. 2B). However,
both atrial and ventricular chambers in TACEZn/Zn mice
by late gestation (E18.5) and neonates (P1) were larger than
in wild-type mice. The ventricular wall at E18.5, particu-
larly the trabecular layer, was thicker in TACEZn/Zn mice
than in wild-type mice, and ventricular trabeculae had deep
recesses (Fig. 2B). At P1 stage, the cardiomyocytes in
TACEZn/Zn knockout hearts were more loosely packed
with larger extracellular spaces (Fig. 2C), though excessive
collagen deposits were not detected by trichrome staining
(data not shown). The diameter of the cardiomyocytes in P1
TACEZn/Zn heart was clearly increased as viewed under
high magnification (Fig. 2C). No valve and chamber septa-
tion defect were observed. Furthermore, the fetal heart en-
largement in E18.5 TACEZn/Zn mice was quantitatively
evaluated by comparison of the isolated heart weight be-
tween wild-type and TACEZn/Zn knockout mice (Table
Fig. 1. Temporo-spatial expression pattern of TACE in mouse fetal heart. (A, B) TACE expression at mRNA level during heart development was measured
by competitive RT-PCR. PCR products were analyzed on agarose gel (A), and the band intensities were quantified to determine the relative levels of TACE
mRNA expression (B). -Actin was used as a control. Significant difference (*, P  0.05) was detected for the difference of TACE mRNA levels between
E16.5 and E18.5. (C, D) TACE protein cellular localization at E16.5 was detected by immunostaining. TACE was dispersed throughout the whole heart, but
the staining in ventricular sepatum and trabeculae was more intense (C). The boxed area in (C) was further viewed under high magnification (D). Scale bar:
200 m. *, Specific staining in lung peripheral epithelial cells is noted as a positive control (Zhao et al., 2001).
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1). Since most TACEZn/Zn fetuses had smaller body size
compared with their littermates, the isolated heart weight
was normalized as the heart weight-to-body weight ratio. In
TACEZn/Zn null mutant mice (/), there was about a
2030% increase (P  0.05) in the heart weight-to-body
weight ratio number compared with the numbers in wild-
type (/) and heterozygous (/) mice, which have a
normal cardiac phenotype.
Fig. 2. Abnormal myocardial development in TACEZn/Zn null mutant mice. (A) Gross view of the hearts isolated from neonatal mice (P1) with genotypes
of wild type (WT) or TACEZn/Zn knockout (KO). The TACEZn/Zn knockout heart is more than twice as big as the wild-type. (B) HE staining of transverse
sections of fetal hearts at different developmental stages. Although no obvious difference was seen at E15.5, enlarged ventricles and thickened myocardium
with deep trabecular recesses were observed at E18.5. Scale bar: 200 m. (C) Cardiomyocyte size and density under high magnification. The diameter of
cardiomyocytes in P1 TACEZn/Zn knockout heart was larger than in wild-type, and the TACEZn/Zn knockout cells were more loosely packed together.
Scale bar: 20 m.
Fig. 3. Comparison of cell proliferation and apoptosis between P1 TACEZn/Zn knockout mouse heart (KO) and its wild-type control (WT). (A, B) Cell
proliferation in neonatal mouse hearts (P1) was measured by BrdU labeling. There were more BrdU-positive cells (brown color) in the ventricular tissue
section stained by anti-BrdU antibody (A, scale bar: 25 m), and the cell proliferation index in TACEZn/Zn knockout mouse heart was quantified as 14
 3% versus 8  1% in wild-type control (B; *, P  0.05). (C) Detection of apoptotic cells by TUNEL assay. Only a few apoptotic cells were detected
in both TACEZn/Zn knockout and wild-type control sections, as pointed by black arrows. Scale bar: 25 m.
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Increased cell proliferation in newborn of TACEZn/Zn
knockout mouse hearts
The heart enlargement seen in the TACEZn/Zn knock-
out mice could result from increased cell volume (hypertro-
phy) and/or increased cell number, which is controlled by
the rates of cell proliferation and cell apoptosis. Therefore,
cardiac cell proliferation and cell apoptosis were measured,
although the enlarged cardiomyocytes observed in the
TACEZn/Zn heart could possibly account for the increased
heart size. The index of proliferating cells in the P1 heart, as
shown by BrdU labeling, was significantly higher in the
TACEZn/Zn knockout mice than in wild-type littermate
controls (Fig. 3A and B), although no differences were
observed at earlier developmental stages (E16.5, data not
shown). However, cell apoptosis was similar in the P1
TACEZn/Zn hearts compared with wild-type controls
(Fig. 3C).
Changes of cardiac specific gene expression in
TACEZn/Zn knockout heart
In order to further characterize TACEZn/Zn knockout
heart, changes of several cardiac-specific gene expression
were evaluated by real-time PCR (Fig. 4). These genes
included atrial natriuretic factor (ANF), B-type natriuretic
peptide (BNP), - and -myosin heavy chain (-MyHC and
-MyHC), skeletal -actin, and cardiac -actin. Alteration
of this gene expression is usually associated with abnormal
cardiac structure and contractile function, such as myocar-
dial hypertrophy. In the TACEZn/Zn null mutant mouse
heart at P1 stage, expression of ANF, skeletal -actin,
cardiac -actin, and -MyHC was significantly increased,
especially skeletal -actin, where a sixfold increase was
detected. However, no changes of BNP and -MyHC ex-
pression were observed.
Altered EGFR family proteins in TACEZn/Zn knockout
heart
Many of the epidermal growth factor receptor (EGFR)
family proteins, including EGFR, ErbB2, and ErbB4, play
important regulatory roles during myocardial development
and modeling. Ectodomain shedding of heparin-binding
EGF (HB-EGF), one of the EGFR ligands, is required for
transactivation of EGFR during G-protein-coupled receptor
(GPCR)-activated cardiac hypertrophy (Prenzel et al.,
1999), while ErbB4 is essential for normal myocardial tra-
beculation (Gassmann et al., 1995; Meyer and Birchmeier,
1995). Since TACE has been shown to regulate the ectodo-
main shedding of ErbB4 and possibly HB-EGF in vitro (Rio
et al., 2000; Merlos-Suarez et al., 2001), we therefore
examined EGFR and ErbB4 proteins in TACEZn/Zn
knockout heart. We found that expression of EGFR in
TACEZn/Zn knockout mouse heart at P1 stage is dramat-
ically decreased compared with wild type control (Fig. 5),
and the related phosphorylation of EGFR was also reduced
(data not shown). Moreover, cleavage of ErbB4 was re-
duced, but not abrogated in TACEZn/Zn null mutant heart
tissue at P1 stage, as shown by increased full-length ErbB4
(180 kDa, Fig. 5) and reduced cleaved product (80 kDa, Fig.
5) compared with wild-type control. If ectodomain shedding
of receptor ErbB4 is a negative regulatory step for neuregu-
lin-ErbB4 pathway, reduced cleavage of ErbB4 would pos-
sibly facilitate or sustain ErbB4-mediated signaling, result-
ing in excessive growth of cardiomyocytes, particularly in
trabeculae, a phenotype seen in our TACEZn/Zn knockout
mice.
Altered Mitogen Activated Protein Kinase (MAPK)
pathway signaling activities in TACEZn/Zn knockout
heart
The intracellular mitogen-activated protein kinase
(MAPK) pathway, including ERKs, P38, and JNKs, medi-
ates a variety of cell surface receptor signaling such as
EGFR in cells. Studies have indicated that activation of p38
and ERK5, as well as their upstream MAPK kinases can
induce cardiac hypertrophy (Wang et al., 1998a,b; Nemoto
et al., 1998; Nicol et al., 2001). We therefore evaluated the
activation of MAPK pathways by comparing the level of
their phosphorylated active form in P1 mouse heart tissues
between different TACE genotypes (Fig. 6). Interestingly,
we found that the level of phosphorylated p38 (pp38) was
increased, while phosphorylated ERK2 (pERK2) and JNK
(pJNK) were decreased in TACEZn/Zn knockout heart
compared with its wild-type littermate controls. No changes
of ERK1 and ERK5 phosphorylation were observed (data
not included).
Discussion
Myocardial development exhibits a unique pattern of
organogenesis (Olson and Srivastava, 1996; MacLellan and
Schneider, 2000). The enlargement of the fetal heart is
mainly achieved by cardiomyocyte proliferation. Whereas,
shortly after birth, the cardiomyocyte permanently exits the
cell cycle and loses its proliferative ability, the heart is then
Table 1
Comparison of E18.5 fetal heart weights between wild-type and
TACEZn/Zn null mutant mice
Genotype TACE/ TACE/ TACE/
No. of samples 10 19 10
Body weight (g) 1.219  0.186 1.234 0.120 1.013 0.151
Heart weight (mg) 11  2 12 1 13 4
Heart weight-to-body
weight ratio (mg/g)
9  2 9  1 13  3a
a TACE/ vs. TACE/, P  0.05; TACE/ vs. TACE/,
P  0.05.
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enlarged primarily by increasing the volume of each cardi-
omyocyte. This complicated process is coordinated by
many factors derived from the cardiomyocytes themselves,
as well as from the adjacent epicardial-derived mesenchy-
mal cells (Manner et al., 2001). Changes in level or activity
of such homeostatic factors may contribute to developmen-
tal anomalies of the heart, and consequently abnormal car-
diac “pump” function. Our data suggest that TACE is one of
the factors involved in normal myocardial development.
TACE expression in fetal heart was detected at both the
mRNA and protein levels. Although a relative reduction in
TACE expression in total heart tissue was observed during
mid–late gestation, a slight and transient increase of TACE
mRNA expression was observed in E18.5 heart when most
cardiomyocytes lose proliferation potential. This may sug-
gest that TACE possibly regulate cardiomyocyte prolifera-
tion during the late fetal stage of cardiac development.
Using immunohistochemistry, TACE protein was detected
throughout the whole fetal heart. However, the increased
TACE distribution on the endocardial side of the myocar-
dial wall, particularly in trabeculae, may indicate an impor-
tant role for TACE in trabecular formation. Null mutation of
the TACE gene resulted in a severe abnormality in late
gestational (E18.5) and neonatal (P1) hearts. These included
enlarged total heart size and a 2030% increase in heart
weight-to-body weight ratio. Morphologically, the thickness
of myocardial wall, particularly the trabecular layer, was
substantially increased in TACEZn/Zn knockout mouse
heart. The enlargement of both left and right sides of the
postnatal heart excludes the possibility that the cardiac ab-
normality is a compensatory response to a particular periph-
eral circulation problem such as reduced pulmonary circu-
lation. Moreover, in the TACEZn/Zn knockout heart, the
cardiomyocytes were enlarged, and were more loosely
packed, with larger extracellular spaces, a similar patholog-
ical phenotype to that observed in “noncompaction of ven-
tricular myocardium” (Chin et al., 1990). The contents fill-
ing the extracellular spaces need to be further examined
since no collagen accumulation was detected by trichrome
staining. Unfortunately, the myocardial contractile function
in TACEZn/Zn null mutants is difficult to evaluate by
echocardiography since the null mutant is perinatal lethal.
While the total cardiac phenotype of the TACEZn/Zn
knockout mice is unique, partial phenotypes have been
observed previously in mice with other genetic deficiencies.
For example, FKBP12 null mutant mice had a similar phe-
notype of heart enlargement accompanied by hypertrophic
trabeculation. But the cardiac abnormality occured earlier
(E14.5 to birth), and an additional ventricular septal defect
also existed in the FKBP12 knockout mouse heart (Shou et
al., 1998). Similarly, mice with HB-EGF gene knockout had
additional heart valve malformations in addition to enlarged
heart by late gestation, with unchanged cardiomyocyte size
(Iwamoto et al., 2003). The cardiac hypertrophic abnormal-
ities occurring in mice with several other genetic mutation,
such as in PTEN knockout mice and in MEK5 transgenic
mice, were frequently observed in adults (Crackower et al.,
2002; Nicol et al., 2001), and were associated with different
molecular changes. Therefore, TACE appears to play a
unique and essential role in heart development at the peri-
natal stage.
The possible cellular mechanisms underlying the abnor-
mal cardiac development in TACEZn/Zn null mutant mice
have been explored in our current study. Although a cardi-
omyocyte hypertrophy was observed in the enlarged
TACEZn/Zn knockout mouse hearts, cardiac enlargement
can also result from increased cardiomyocyte number (hy-
perplasia). Cell proliferation and cell apoptosis were then
compared in P1 hearts between different TACE genotypes,
and our data suggest that increased cell proliferation, but not
reduced cell apoptosis, may also contribute to the abnor-
mally enlarged heart seen in TACEZn/Zn knockout mice.
Therefore, TACE might be involved in processing regula-
tory factors on the cell surface, which promote cells to exit
from the cell cycle and control cell growth in proper size.
Also, TACE may affect cell compaction through either
direct effects on myocardial cells or indirect effects on
mesenchymal cells.
However, the molecular mechanisms of TACE involve-
ment in fetal heart development and modeling are still
unknown. TACE, as a cell surface sheddase, is able to
specifically cleave many cell surface target proteins in a
variety of cell types (Killar et al., 1999). The biological
significance of such protein ectodomain shedding varies
depending on the functions of the target proteins. For in-
stance, cleavage-mediated release of cytokines and growth
factors from cell surface may lead to activation and/or distal
and broad-range effects. In contrast, cleavage of active
receptor on cell surface may reduce its ligand binding ac-
tivity and downregulate the related signaling pathway.
There are several TACE-targeted proteins that may attribute
to abnormal cardiac development in TACEZn/Zn null mu-
tant mice. TGF is a candidate because most of the other
TACEZn/Zn knockout phenotypes, such as failure of eye-
lid fusion, abnormal hair and skin structure as previously
reported, were also observed in TGF null mutant mice
(Luetteke et al., 1993). However, there was no perinatal
lethality and abnormal cardiac phenotype in TGF- knock-
out mice. Whether abrogation of TGF activity in combi-
nation with loss of other TACE-targeted protein functions
results in the abnormal heart development needs further
investigation. Interestingly, expression of EGFR, one of the
TGF receptors, and the related protein phosphorylation
was dramatically reduced in the TACEZn/Zn knockout
heart, indicating that EGFR signaling pathway is attenuated
in the absence of functional TACE. Studies by other groups
have shown that GPCR-mediated cardiac hypertrophy in
adult heart usually requires HB-EGF-mediated transactiva-
tion of EGFR and other EGFR family members (ErbB2 and
ErbB4) (Asakura et al., 2002; Iwamoto et al., 2003). How-
ever, ventricular-specific ErbB2 conditional knockout mice
exhibited ventricular chamber dilation, cardiomyocyte hy-
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pertrophy, and diminished cardiac function (Ozcelik et al.,
2002; Crone et al., 2002). ErbB2 is thought to be activated
through forming heterodimers with other EGFR receptor
family members, such as EGFR and ErbB4. Whether re-
duced EGFR activation in TACEZn/Zn knockout mice
results in reduced ErbB2 activation through less het-
erodimer formation, and correlates with cardiomyocyte hy-
pertrophy is unknown.
Furthermore, another member of the EGFR family,
ErbB4, was found to undergo less cleavage in the P1
TACEZn/Zn knockout heart, which is consistent with pre-
vious reports that ErbB4 was subject to constitutive and
regulated TACE-mediated protein cleavage in cultured cells
(Rio et al., 2000). ErbB4 and its interacting neuregulin
family of EGF like ligands are already known to play
essential roles in trabeculation (Gassmann et al., 1995;
Meyer and Birchmeier, 1995). Mice with neuregulin or its
cognate receptor ErbB4 null mutations fail to form trabec-
ulae and die at midgestation. In the TACEZn/Zn knockout
mice, the hypertrophic trabecular phenotype and reduced
cleavage of cell surface ErbB4 were observed. We speculate
that TACE may work through cleavage of cell surface
ErbB4, or possibly other neuregulin receptors, to regulate
Fig. 4. Cardiac-related gene expression in P1 TACEZn/Zn knockout heart.
(A) Real-time quantitative RT-PCR detection. Only the graphs for cardiac
-actin and the control GAPDH gene detection are shown here as repre-
sentative examples. The Ct values were the cross-point between the hori-
zontal threshold line (brown) and the amplified fluorescence curves; green:
TACEZn/Zn knockout sample; red: wild-type control. (B) The ratios of
each detected gene in the samples of TACEZn/Zn knockout tissues to that
in wild-type controls were calculated. Significantly increased expression of
ANF (1.3-fold), -MyHC (1.4-fold), skeletal -actin (6.1-fold), and car-
diac -actin (1.9-fold) was detected, while expression of BNP and
-MyHC remained same. *, P  0.05.
Fig. 5. Changes of EGFR receptor family proteins in TACEZn/Zn knockout
hearts (KO) compared with that in wild-type controls (WT) by Western blot.
EGFR expression in P1 TACEZn/Zn knockout hearts was significantly re-
duced. In addition, reduced ErbB4 cleavage was also observed in TACEZn/
Zn knockout heart. An anti-ErbB4 antibody that recognizes ErbB4 cytoplas-
mic epitopes was used for western analysis. A full length transmembrane
ErbB4 was detected as a 180-kDa band, and the remaining fragment after
proteolytic ectodomain shedding was detected as an 80-kDa band. The pro-
teolytic cleavage of ErbB4 was still observed in TACEZn/Zn knockout
samples, as both 180- and 80-kDa bands were detected. However, the intensity
of the protease-cleaved ErbB4 protein band was significantly reduced, while
the intensity of the full-length ErbB4 protein band was clearly increased in the
TACEZn/Zn knockout heart compared with wild-type control, indicating less
ectodomain shedding of ErbB4. GAPDH was used as a loading control.
Fig. 6. Western blot analysis of phosphorylated MAPKs in TACEZn/Zn
knockout hearts. Reduced phosphorylation of ERK2 (pERK2) and JNK
(pJNK), and increased phosphorylation of p38 (pp38) were detected in P1
TACEZn/Zn knockout heart samples (KO) compared with the wild-type
controls (WT). Equal expression of the related MAPK protein was con-
firmed by Western blot using the antibodies recognizing MAPK proteins.
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fetal cardiac trabeculation. On the other hand, other known
or unknown TACE-mediated shedding molecules may also
be possibly involved in mediating the TACEZn/Zn knock-
out myocardial phenotype.
Downstream of the cell surface proteins, we have exam-
ined the MAPK pathway, which is a very important intra-
cellular signal transducer connecting cell surface stimuli to
nuclear effectors. Activation of MAPK in the heart can
occur after GPCR agonist stimulation and other cellular
stress (Clerk and Sugden, 1999; Sugden and Clerk, 1998).
MAPKs can be divided into three subfamilies: ERKs, JNKs,
and p38. The role of each individual MAPK pathway in
cardiac growth and hypertrophic response is not fully un-
derstood. In the TACEZn/Zn knockout heart, protein levels
of MAPKs were not changed, but protein phosphorylation,
which is tightly correlated to the MAPK activity, was
changed. Reduced phosphorylated JNK and ERK2 were
obviously detected in TACEZn/Zn knockout heart tissues,
while p38 phosphorylation was clearly increased, suggest-
ing that JNK and PRK2 pathways are downregulated, while
p38-mediated pathway is activated. Whether reduced acti-
vation of JNK and ERK2 is a consequence of the reduced
cell surface EGFR expression and activation seen in the
TACEZn/Zn knockout heart needs to be addressed in fu-
ture experiments. Similarly, the relationship between p38
activation and possibly overactivated ErbB4 due to reduced
cleavage on the cell surface is another very interesting
question.
In summary, the unique cardiac phenotype described
herein suggests that TACE-mediated protein ectodomain
shedding may be a critical regulatory process in controlling
cardiomyocyte proliferation and trabeculation, effecting ap-
propriate myocardial growth and modeling during late ges-
tation.
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